# EDGAR Filing Document

**Accession Number:** 0001348362
**File Stem:** 0001640334-23-000112
**Filing Date:** 2023-1
**Character Count:** 5633
**Document Hash:** dda32bc434ac6e93c67fc1cde7c7432c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001640334-23-000112.hdr.sgml**: 20230123

**ACCESSION NUMBER**: 0001640334-23-000112

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230123

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230123

**DATE AS OF CHANGE**: 20230123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lexaria Bioscience Corp.
- **CENTRAL INDEX KEY:** 0001348362
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 202000871
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0831

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39874
- **FILM NUMBER:** 23543936

**BUSINESS ADDRESS:**
- **STREET 1:** 100 - 740 MCCURDY ROAD
- **CITY:** KELOWNA
- **STATE:** A1
- **ZIP:** V1X 2P7
- **BUSINESS PHONE:** 250-765-6424

**MAIL ADDRESS:**
- **STREET 1:** 100 - 740 MCCURDY ROAD
- **CITY:** KELOWNA
- **STATE:** A1
- **ZIP:** V1X 2P7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LEXARIA CORP.
- **DATE OF NAME CHANGE:** 20080229

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Lexaria Corp.
- **DATE OF NAME CHANGE:** 20051229

?xml version="1.0" encoding="utf-8"?lxrp_8k.htm

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **<u>January 23, 2023</u>**

---

| |
|:---|
| **LEXARIA BIOSCIENCE CORP.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-52138**  | **20-2000871** |
| (State or other jurisdiction<br> of incorporation) | (Commission <br>File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **100 – 740 McCurdy Road, Kelowna, BC Canada**  | **V1X 2P7** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code <u>**(250) 765-6424**</u> 

__________________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading** <br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share<br>Warrants to Purchase Common Stock | LEXX<br>LEXXW | The Nasdaq Capital Market<br>The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure** |

---

Lexaria Bioscience Corp. has engaged the former President of GW Pharmaceuticals USA, Julian Gangolli, as a Strategic Advisor. Mr. Gangolli oversaw approval by the US Food and Drug Administration ("FDA") of the first and only pure cannabidiol drug ever approved by the FDA, Epidiolex®, and its subsequent successful commercialization in the USA leading to the acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals in 2021 in a $7.2 billion transaction.

Prior to that, Mr. Gangolli was a senior member of the Allergan management team from 1998 onwards that transformed Allergan into one of the leading specialty pharmaceutical companies in the US and was also a member of their Executive Management team that oversaw the sale of Allergan to Actavis in 2015.

Stock options valid to purchase 5,000 shares of the Company are being issued to Mr. Gangolli with an exercise price of $2.73 per share, valid for 5 years from the date of issuance.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

2<br>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| |
|:---|
| **LEXARIA BIOSCIENCE CORP.** |
| /s/*Chris Bunka* |
| **Chris Bunka** |
| CEO, Principal Executive Officer |
| Date: January 23, 2023 |

---

3<br>